Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center (Collaborative UG3/UH3 Clinical Trial

The summary for the Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center (Collaborative UG3/UH3 Clinical Trial grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center (Collaborative UG3/UH3 Clinical Trial: The goal of this funding opportunity for a Clinical Coordinating Center is to support a clinical trial which will test intervention(s) to reduce the progression of coronary atherosclerosis among young adults under the age of fifty years old who are at low or borderline 10-year risk ( 7.5%) for their first an atherosclerotic cardiovascular disease (ASCVD) event, yet at high lifetime risk of developing cardiovascular disease (CVD). This opportunity will support a two-phased primary prevention clinical trial that will first efficiently screen the appropriate population eligible for the intervention and second determine which intervention(s) are most efficacious at reducing the onset or slowing the progression of subclinical coronary atherosclerosis. It is expected that phase one will overlap with phase two. Trial participants who are identified as meeting the subclinical coronary atherosclerosis criteria for enrollment in the screening stage will be immediately enrolled in stage two even although stage one recruitment will continue until the trial is completely enrolled. It is expected that the trial will have three arms. One will be a control or comparison arm and the second and the third arm will test different interventions than the control arm. The control arm should be current guideline based behavioral interventions. One of the two non-control arms is expected to involvement pharmacological intervention(s) with definite evidence of efficacious for primary prevention in older high risk adults such as LDL- lowering therapy and the other arm may involve intervention(s) with less definite evidence of primary prevention efficacy in older adults The long range goal of this research strategy is to determine if earlier treatment prevents more CVD than current guideline recommended treatment. Applications for both a CCC and a DCC must be submitted on the same application due date for consideration by NHLBI.

Federal Grant Title:	Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center (Collaborative UG3/UH3 Clinical Trial
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-25-010
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.837
CFDA Descriptions:	Information not provided
Current Application Deadline:	October 28th, 2024
Original Application Deadline:	October 28th, 2024
Posted Date:	July 10th, 2024
Creation Date:	July 10th, 2024
Archive Date:	December 3rd, 2024
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	July 10th, 2024

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-25-010.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Single Source: Bench to Bassinet Congenital Heart disease Advancing New understanding in G...; • Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Ad...; • Chronic Kidney Disease in Children Central Biochemistry Laboratory (U24 Clinical Trial Not...; • Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in...; • Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in...; • The Relationship Between Hypertension and Inflammation; • Community-Responsive Interventions to Reduce Cardiovascular Risk in American Indians and A...; • Weight Loss in Obese Adults with Cardiovascular Risk Factors: Clinical Interventions (U01)
More Grants from the National Institutes of Health: • Time-Sensitive Evaluation of Policies Affecting Health Behaviors and Chronic Disease Risk ...; • NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements...; • Single Source: Bench to Bassinet Congenital Heart disease Advancing New understanding in G...; • NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32); • NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)